Breanna O'Reilly

Breanna O'Reilly is an Analyst on the Investment Team at RA Capital Management, a leading life sciences investment firm based in Boston, MA. In her role, she leverages her scientific expertise to conduct in-depth due diligence and support investment decisions across the life sciences sector, with a particular focus on biotechnology and healthcare innovation. She is actively involved in evaluating early-stage and growth opportunities, contributing to RA Capital's evidence-based investment strategy.

Breanna specializes in investments within biotechnology, medical devices, and diagnostics, with a strong emphasis on companies leveraging cutting-edge technologies such as cell and gene therapy, AI-driven drug discovery, and novel therapeutic platforms. Her work involves close collaboration with RA Capital's TechAtlas research division, which provides market intelligence and technical diligence to inform investment theses and portfolio company support.

Prior to joining RA Capital, Breanna earned a PhD in Biomedical Engineering from Boston University and a BS in Biomedical Engineering from the University of Rochester. She has served as a Board Observer for Indapta Therapeutics and CellCentric, supporting the strategic development of pioneering cell therapy and epigenetics companies. Her background combines rigorous scientific training with practical investment experience, positioning her as a key contributor to RA Capital's mission of advancing transformative healthcare solutions.